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Background: Presentation of identical HIV-1 peptides by closely related Human Leukocyte Antigen class I (HLAI)
molecules can select distinct patterns of escape mutation that have a significant impact on viral fitness and disease
progression. The molecular mechanisms by which HLAI micropolymorphisms can induce differential HIV-1 escape
patterns within identical peptide epitopes remain unknown.
Results: Here, we undertook genetic and structural analyses of two immunodominant HIV-1 peptides, Gag180–188
(TPQDLNTML, TL9-p24) and Nef71–79 (RPQVPLRPM, RM9-Nef) that are among the most highly targeted epitopes in
the global HIV-1 epidemic. We show that single polymorphisms between different alleles of the HLA-B7 superfamily
can induce a conformational switch in peptide conformation that is associated with differential HLAI-specific escape
mutation and immune control. A dominant R71K mutation in the Nef71-79 occurred in those with HLA-B*07:02 but
not B*42:01/02 or B*81:01. No structural difference in the HLA-epitope complexes was detected to explain this
observation.
Conclusions: These data suggest that identical peptides presented through very similar HLAI landscapes are
recognized as distinct epitopes and provide a novel structural mechanism for previously observed differential HIV-1
escape and disease progression.
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The human leukocyte antigen (HLA) locus on chromo-
some 6 is the most polymorphic region of the human
genome. The extreme diversity of HLA class I (HLAI)
loci allows optimal binding of peptides derived from the
vast array of environmental pathogens [1]. The HLAI
residues that are polymorphic are mainly those forming
the peptide-binding groove, which contains six binding
pockets (A to F) that define the size and chemical char-
acteristics of the specific peptide repertoire that can be
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unless otherwise stated.between peptide and HLAI is usually governed by the
compatibility of residues at the N- and C-terminus of
the peptide (peptide anchor residues) within the highly
polymorphic binding pockets. Cognate T-cell receptors
(TCRs) expressed on CD8+ T-cells detect pathogen-
derived peptides presented by HLAI molecules on the
surface of infected cells [2].
Minor differences between the HLAI molecules ex-
pressed (‘HLAI micropolymorphisms’), even of a single
amino acid, can have a profound impact on both T-cell
immunity and disease outcome during a range of infec-
tions, including HIV-1 [3-8]. This disparity has been
partly explained by the selection of escape mutations
that have different consequences for viral fitness [8-10].
For example, the dominant HIV-1-specific epitope re-
stricted by two closely-related HLAI molecules within
the B7 superfamily, HLA-B*42:01 and HLA-B*81:01, isral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[11,12]. The escape mutation selected in each case dif-
fers, with variation most commonly arising at Gag-182
(position-3 in the epitope) in HLA-B*42:01-positive sub-
jects, and at Gag-186 (position-7) in HLA-B*81:01-
positive subjects. In vitro studies indicate that the escape
mutants selected at Gag-186 have a dramatic negative
impact on viral replication capacity, in contrast to the
minimal effect of mutation at Gag-182 [13]. HLA-
B*81:01, together with HLA-B*57 and HLA-B*58:01, is
one of the group of HLAI molecules most strongly asso-
ciated with immune control of HIV-1 [5,14,15] and the
viral replicative capacity in HLA-B*81:01+ subjects has
been reported to be lower than in subjects expressing
any other allele [13]. The mutation principally respon-
sible for this protective effect is the above-mentioned
HLA-B*81:01-driven T186S variant that fails to yield
replicating virus stocks in studies of C clade virus [13].
This is in line with the lower viral loads and higher CD4
counts observed in HLA-B*81:01 positive subjects in
studies of exclusively C-clade infection [9,14,16]. Not-
ably, in a study of cohorts in Zambia, Rwanda and
Kenya involving several clades of virus, including clade
A which carries a different consensus residue at Gag-
186, stable CD4 counts but not lower viraemia was ob-
served in association with HLA-B*81:01 [15].
In this study we focus on two HIV-1-specific epitopes
and their presentation by 4 different members of the
HLA-B7 superfamily, HLA-B*07:02, HLA-B*42:01, HLA-
B*42:02 and HLA-B*81:01. These alleles are highly preva-
lent in Sub-Saharan Africa, the region worst afflicted by
the HIV-1 pandemic, one or more being expressed in
35-40% of people comprising these populations [14]. The
identical TL9-p24 and Nef71–79, RPQVPLRPM (RM9-Nef)
epitopes are presented by these alleles, and represent two
of the dominant HIV-1-specific responses in Southern
African study cohorts [14], being recognised by approxi-
mately 70% and 40%, respectively, of subjects expressing
HLA B7-supertype alleles, and targeted by approximately
25% and 20%, respectively of all subjects in Southern
African study cohorts, irrespective of HLAI type [14,17].
In the case of both epitopes, TL9-p24 and RM9-Nef,
distinct patterns of escape mutations are induced by differ-
ent HLAI molecules within the B7 superfamily [17]. We
here have undertaken a genetic and structural approach to
better understand the molecular mechanisms by which
HLAI micropolymorphisms can influence the precise na-
ture of T-cell escape and immune control through identi-
cal HIV-1 epitopes. These data demonstrate that even a
single HLAI polymorphism can switch the conformation
of a peptide in the HLAI binding groove, substantially al-
tering both the peptide residues positioned to contact in-
coming TCRs, and consequently of the impact of variation
at different residues within the same epitope.Results
HLAI micropolymorphisms result in distinct targeting
frequencies and selection pressure through two HIV-1
epitopes
We studied four members of the HLA-B7 superfamily,
HLA-B*07:02, HLA-B*42:01, HLA-B*42:02 and HLA-
B*81:01. These closely-related HLAI molecules restrict
both distinct and identical HIV-1 epitopes [4,7,18]. The
differences in sequence between HLA-B*07:02, B*42:01,
B*42:02 and B*81:01 are small (Figure 1A). Atomic reso-
lution of these HLA-B molecules (crystallographic statis-
tics in Additional file 1: Tables S1 and S2) demonstrate
that all of the polymorphic positions are part of the HLAI
peptide binding pockets (Figure 1B-E) and therefore po-
tentially affect peptide presentation to CD8+ T cells.
To better understand the mechanisms underlying the
observed differential HIV-1 selection pressure imposed
on HIV-1 by distinct HLAI molecules within the B7
superfamily, we focused on two epitopes, TL9-p24 and
RM9-Nef, that dominate the HIV-1-specific CD8 T-cell
response in the Southern African HIV-1 epidemic [14,17].
These two epitopes were presented by all four of these
HLAI molecules, other than TL9-p24 which was pre-
sented by all except HLA-B*42:02 (Figure 2A). TL9-p24,
dominantly targeted through HLA-B*42:01 and HLA-
B*81:01 and subdominantly through HLA-B*07:02, had
a peptide-HLAI (pHLAI) stability of >0.7 h and Tm =
49-55°C, whereas the lack of TL9-p24 targeting via HLA-
B*42:02 was associated with low pHLAI stability (<0.2 h,
Tm = 37°C) [7]. RM9-Nef, however, was presented by all 4
different HLAIs, with pHLAI stabilities ranging from 1.7 h
to 22.4 h (Tm = 52-66°C) (Figure 2B-D).
Sequence analysis of >1,200 HIV-1 C-clade infected in-
dividuals confirmed striking differences in HLAI-driven
selection pressure within both epitopes (Figure 2E) and
(Table 1). Of note, selection for the above-mentioned
T186S at position 7 of the TL9-p24 epitope (31%, P =
2×10−24) was only significant in HLA-B*81:01-positive
individuals. Distinct patterns of selection were also ob-
served for RM9-Nef, even though this epitope was simi-
larly targeted irrespective of the B7 superfamily HLA-B
allele expressed (34%-54%). HLA-B*07:02 expressing in-
dividuals exhibited strong selection at P1 in the epitope
(R71K: 41%, P = 7×10−5), whereas HLA-B*81:01 express-
ing individuals showed selection of variants at P6 of the
epitope (L76V/T/I, L76X, P = 2×10−43) with no selection
mediated by HLA-B*42:01 and HLA-B*42:02 on this
RM9-Nef epitope (Figure 2F) (Table 1).
Thus, HLAI micropolymorphisms among these 4
HLA-B alleles result in distinct patterns of immunodo-
minance at a population level. However, even when the
frequency of recognition of epitopes was similar, such as
TL9-p24 targeting in HLA-B*42:01-positive or HLA-
B*81:01-positive subjects; and RM9-Nef targeting in
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Figure 1 Micropolymorphisms within HLA-B*07:02, HLA-B*42:01, HLA-B*42:02 and HLA-B*81:01 molecules. (A) HLAI residue
polymorphisms within α1 domain (top) and α2 domain (bottom) aligned to HLA-B*07:02. (B-E) The HLAI peptide binding groove shown as grey
cartoon with each position in each HLAI coloured individually and shown as sticks for (B) HLA-B*07:02, (C) HLA-B*42:01, (D) HLA-B*42:02 and
(E) HLA-B*81:01, at atomic resolution.
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family HLAI molecules, selection pressure on HIV-1
was HLAI-specific.
A conformational switch induces altered presentation of
TL9-p24 by HLA-B*81:01 compared to HLA-B*07:02 and
HLA-B*42:01
We hypothesised that differential HLAI-specific selec-
tion pressure operating on the same epitope may result
from structural differences in the HLA-peptide complex.
To explore this notion, we first solved the atomic struc-
tures of HLA-B*07:02, HLA-B*42:01 and HLA-B*81:01
with TL9-p24. In addition, we solved the atomicstructures of HLA-B*07:02, HLA-B*42:01, HLA-B*42:02
and HLA-B*81:01 with RM9-Nef (see below). All struc-
tures were determined to extremely high resolutions, be-
tween 1.18 Å and 2.09 Å, with crystallographic Rwork/
Rfree ratios within accepted limits as shown in the theor-
etically expected distribution [19] (Additional file 1:
Tables S1 and S2). The electron density around the
HLAI binding groove and the peptide was unambiguous
in all of the structures.
The total number of contacts, buried surface area and
surface complementarities were comparable in TL9-p24
structures in complex with HLA-B*07:02, HLA-B*42:01
and HLA-B*81:01 (Table 2). The overall conformation of
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Figure 2 TL9-p24 and RM9-Nef immunodominance, pHLAI stability and differential selection pressure for HLA-B*07:02, HLA-B*42:01,
HLA-B*42:02 and HLA-B*81:01. (A) Unbiased screening of n = 1,009 individuals with OLP-25 (GATPQDLNTMLNTVGGH) containing TL9-p24 and
OLP-76 (EVGFPVRPQVPLRPMTFK) containing RM9-Nef of which n = 76 where HLA-B*07:02+, n = 154 where HLA-B*42:01+, n = 22 where HLA-B*42:02+
and n = 96 where HLA-B*81:01+. Individuals expressing HLA-B*39:10 (n = 30) were excluded as they also target TL9-24 and RM9-Nef. (B) TL9-p24
(TPQDLNTML) and RM9-Nef (RPQVPLRPM) pHLAI stability (binding half-life, h) against indicated HLA-B molecules. (C, D) CD thermal denaturation curves
recorded at 218 nm are shown for selected pHLAI samples. Dots represent measured values fitted assuming a 2-state trimer-to-monomer transition
(solid lines) as described in Methods. Insets show bar graphs of the thermal stability with respect to melting temperature (upper) and van’t Hoff’s
enthalpy of unfolding (lower panel) using the same color code as in B. (E, F) Intraepitope HIV-1 polymorphisms for (E) TL9-p24 shown on the X-axis for
Q182X as peptide position 3 and T186S as position 7 and (F) for RM9-Nef R71K as for peptide position 1 and L76X as position 6 and expressed as the
percentage of total viral sequences for n = 1,327 HIV-1 infected individuals of which n = 189 expressed HLA-B*07:02, n = 436 expressed HLA-B*42:01,
n = 56 expressed HLA-B*42:02 and n = 213 expressed HLA-B*81:01. Only Q < 0.05 is shown with ***indicating P < 0.0002 and **P < 0.002 compared
to HLAI mismatched individuals.
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and HLA-B*42:01 was virtually identical, with Pro2 and
Leu9 acting as the main peptide anchor residues and
Asp4, Leu5, Thr7 and Met8 pointing away from the
groove for potential interactions with TCRs (Figure 3A).Although peptide positions 1–4 and 8–9 were in similar
orientations in both HLA-B*07:02-TL9, HLA-B*42:01-
TL9 and HLA-B*81:01-TL9 structures, residues 5–7 in
the HLA-B*81:01-TL9 structure, which differs in the
peptide-presentation platform by just 4 and 3 residues
Table 1 HLA-B*07:02, 42:01, 42:02 and 81:01-associated TL9-p24 and RM9-Nef HIV-1 polymorphisms
Epitope HLA-B HXB2 location Escape variant selecteda Sequenceb % HLA match % HLA mismatch P Qc N
TL9-p24 42:01 182 T EGATPTDLNTMLNTV 9 1 7.0E-07 2.4E-04 1279
81:01 177 D DGATPQDLNTMLNTV 7 1 4.4E-05 1.1E-02 1283
81:01 182 E EGATPEDLNTMLNTV 5 0 2.1E-08 7.6E-06 1282
81:01 182 G EGATPGDLNTMLNTV 8 1 6.2E-06 1.8E-03 1281
81:01 182 S EGATPSDLNTMLNTV 21 3 6.2E-12 4.3E-09 1277
81:01 186 S EGATPQDLNSMLNTV 31 3 1.8E-24 8.5E-21 1285
81:01 191 I EGATPQDLNSMLNTI 9 2 3.2E-06 9.6E-04 1288
RM9-Nef 07:02 71 K FPVKPQVPLRPMTYK 41 6 7.4E-05 2.4E-02 1293
42:02 81 F FPVRPQVPLRPMTFK 34 9 1.4E-04 4.0E-02 1126
81:01 76 V FPVRPQVPVRPMTYK 34 6 3.3E-16 4.8E-13 1327
81:01 76 T FPVRPQVPTRPMTYK 17 1 1.9E-15 2.3E-12 1327
81:01 76 I FPVRPQVPIRPMTYK 7 0 4.0E-06 2.1E-03 1327
aEscape polymorphism shows the amino acid selected in that particular HXB2 location, also indicated by bold face.
bEpitope is italics with the consensus shown for +/- 3 amino acids; bold indicates the site of polymorphism.
cOnly Q-values <0.05 are included.
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pectively, were flipped into the opposite orientation
(Figure 3A). This ‘conformational switch’ resulted in
Leu5 and Thr7 acting as secondary anchor residues in
HLA-B*81:01-TL9, as opposed to being solvent exposed
in HLA-B*07:02-TL9 and HLA-B*42:01-TL9 complexes.
In the HLA-B*81:01-TL9 complex, Asn6 of the peptide
acted as the dominant feature pointing out of the
groove. In contrast, the same residue served as a second-
ary anchor residue in HLA-B*07:02-TL9 and HLA-
B*42:01-TL9. Thus, unexpected and striking differences
in TL9-p24 conformation transform the epitope fromTable 2 HLA-TL9 contact table
B0702 B8101 B4201
TL9 VdW HB/SB VdW HB/SB VdW HB/SB
Thr1 26 4 27 5 23 4
Pro2 24 0 22 0 21 0
Gln3 28 1 26 1 24 2
Asp4 4 1 6 2 5 1
Gln5 0 0 2 1 0 1
Asn6 15 1 6 0 4 1
Thr7 9 3 5 2 7 0
Met8 23 2 8 0 25 2
Leu9 23 4 15 3 24 4
Total 152 16 117 14 133 15
BSA (Å) 1651.8 1726.2 1654.2
SC (Å) 0.741 0.741 0.714
HB = hydrogen bond, SB = salt bridge, vdW = van der Waals interactions,
BSA = buried surface area, SC = surface complementarity.
*A 3.4 Å cut-off was used for HBs and SBs, and a 4 Å cut-off was used for vdW.the perspective of an incoming TCR restricted by HLA-
B*81:01 compared to HLA-B*07:02 and HLA-B*42:01.
To explain how minor HLAI polymorphisms could ac-
count for this distinct peptide conformation, we focused
on two polymorphic residues, at position 147 and 156 of
the three HLAI molecules presenting TL9-p24. HLA-
B*07:02 and HLA-B*42:01 have Trp at position 147,
whereas HLA-B*81:01 has Leu147 (Figure 3B). This side
chain had a substantial impact on the position of the α2
helix of the HLAI, evident by a movement of 1.7 Å to-
wards the peptide for HLA-B*81:01 (Figure 3B), and
altered the interaction between the HLAI and the C-
terminus of the TL9-p24 peptide. Trp147, in HLA-
B*07:02 and HLA-B*42:01, made three van der Waals
(VdW) contacts with Thr7 and Met8 in the peptide,
compared to just one VdW contact between Leu147 in
HLA-B*81:01 and Met8 (Figure 3C, D), contributing to
the respective peptide conformations.
A second important difference occurred at HLAI resi-
due 156 (with Arg, Asp and Leu at this position in
HLA-B*07:02, HLA-B*42:01 and HLA-B*81:01 respect-
ively) which contributed to the conformational differ-
ences observed at peptide residues Gln3, Asn6 and Thr7
(Figure 3E, showing HLA-B*07:02 and HLA-B*81:01).
The altered position of peptide residue Gln3 in HLA-
B*81:01, compared to that in HLA-B*07:02 and HLA-
B*42:01, forced Asn6 to swing up, out and clear of Gln3
in HLA-B*81:01 (Figure 3F). The smaller side chain of
Leu156 in HLA-B*81:01 compared to the longer Arg156
in HLA-B*07:02 and Asp156 in HLA-B*42:01 (Figure 3E),
enabled peptide residues Leu5 and Thr7 to form interac-
tions stabilizing Asn6 in the flipped orientation in the
HLA-B*81:01 structure (Figure 3G). Overall, therefore,
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Figure 3 TL9-p24 exhibits a unique conformation when presented by HLA-B*81:01. Comparison of the presentation modes of HLA-
B*07:02-TL9 (green sticks), HLA-B*81:01-TL9 (orange sticks) and HLA-B*42:01-TL9 (yellow sticks), the HLAI binding groove is shown as grey cartoon.
(A) Structural alignment of HLA-B*07:02-TL9, HLA-B*81:01-TL9 and HLA-B*42:01-TL9 peptide conformations showing that HLA-B*07:02 and
HLA-B*42:01 present TL9-p24 in identical conformations, whereas in HLA-B*81:01 residues 5–7 in TL9-p24 are presented in a distinct conformation
(arrows pointing up indicate that the corresponding residue is solvent exposed and available for TCR contact, arrows pointing down indicate that
the corresponding residue is buried in the HLA groove; black arrows designate that the residue is in the same orientation in all three structures,
colored arrows indicate different residue conformations according to the colors used in each structure). The positions of the circled residues
(Leu5, Asn6 and Thr7) may be important to explain differential escape when presented by different HLAIs. (B) HLA-B*07:02 and HLA-B*42:01
contain Trp at residue 147, compared to Leu in HLA-B*81:01. This difference generates a 1.7 Å shift in the HLAα1 helix. (C, D) This shift alters
interactions between the HLAI binding groove and residues 7 and 8 in the peptide. (E) HLA-B*07:02 and HLA-B*42:01 contain Arg at residue 156
compared to Leu156 in HLA-B*81:01. This polymorphism alters interactions with the peptide leading to the observed divergent conformations.
(F) TL9-p24 residue Gln3 adopts a slightly different conformation in HLA-B*07:02 and HLA-B*42:01 compared to HLA-B*81:01 which contributes to
the different position of Asn6 in the peptide. (G) TL9-p24 residues Leu5 and Thr7 form a stabilising interaction in the HLA-B*81:01-TL9 structure
that is not present in HLA-B*07:02-TL9, or HLA-B*42:01-TL9. (H) In HLA-B*07:02-TL9 and HLA-B*42:01-TL9, residue Leu5 is the most solvent
exposed residue. However, in HLA-B*81:01-TL9, residue Asn6 assumes this role.
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peptide and the polymorphic residues in HLA-B*81:01,
compared to those of HLA-B*07:02 and HLA-B*42:01,
resulted in the upward display of different residues
within the solvent exposed, central peptide bulge
(Figure 3H).HLAI micropolymorphisms alter direct interactions with
the RM9-Nef peptide, explaining differences in pHLAI
stability and overall epitope presentation
We next analyzed the structures of HLA-B*07:02, HLA-
B*42:01, HLA-B*42:02 and HLA-B*81:01 in complex
with the well characterised RM9-Nef epitope. Pro2 and
Kløverpris et al. Retrovirology  (2015) 12:20 Page 7 of 11Met9 acted as primary anchor residues and Arg1,
Val4 and Arg7 pointed away from the groove for po-
tential TCR interactions (Figure 4A). The total num-
ber of contacts, buried surface area and surface
complementarities were comparable in all four struc-
tures (Table 3). Although the overall conformation of
the RM9-Nef peptide backbone was similar for all 4
HLAI molecules, we observed important differences
in the side chain orientations that could potentiallyR     P   Q V  P   L     R  P
A
Leu6
Leu6
Arg156
Leu156
Gln152
Val152
C D
Trp147
Leu147
Leu6
Figure 4 HLAI polymorphisms contribute to differences in the fine pr
modes of HLA-B*07:02-RM9 (green sticks), HLA-B*81:01-RM9 (orange sticks)
the HLAI binding groove is shown as grey cartoon. (A) Structural alignment o
B*42:02-RM9 peptide conformations showing differences around peptide resi
corresponding residue is solvent exposed and available for TCR contact, black
in the HLA groove; no arrow indicates a position between solvent exposed an
to explain differential escape when presented by different HLAIs. (B) RM9
structure compared to HLA-B*42:01 and HLA-B*42:02. (C) HLA-B*81:01 con
in HLA-B*42:01 and HLA-B*42:02. This polymorphism alters the interactions be
its conformational heterogeneity. (D) HLA-B*81:01 contains a Leu at position 14
polymorphism reduces the interactions between residues Pro8 and Met9 in the
contains a His at position 9 compared to Tyr in HLA-B*07:02, HLA-B*81:01 and H
Pro2 in the peptide and HLA-B*42:02 compared to the other HLAIs.impact T-cell recognition and viral escape, as detailed
below.
Despite distinct selection pressure at position 1 of
RM9-Nef by HLA-B*07:02 (R71K) (Figure 2F) (Table 1),
peptide residue Arg1 was in a similar conformation in
all 4 HLAIs (Figure 4A). However, the altered con-
formation of Leu6 in the RM9-Nef-HLA-B*81:01 com-
plex, compared with the other three complexes has
similarities with the conformational switch described  M
Leu6
3Å
B
E
Pro8
Met9
Pro8
Met9
Pro2
Pro2
Tyr9
His9
esentation mode of RM9-Nef. Comparison of the presentation
, HLA-B*42:01-RM9 (yellow sticks) and HLA-B*42:02-RM9 (pink sticks),
f HLA-B*07:02-RM9, HLA-B*81:01-RM9, HLA-B*42:01-RM9 and HLA-
dues Arg1, Leu6 and Arg7 (black arrows pointing up indicate that the
arrows pointing down indicate that the corresponding residue is buried
d buried). The position of the circled residue (Leu6) may be important
-Nef residue Leu6 undergoes a 3 Å shift in position in the HLA-B*81:01
tains a Leu at position 156 compared to Arg in HLA-B*07:02 and Asp
tween RM9-Nef residue Leu6 and the different HLAIs contributing towards
7 compared to Trp in HLA-B*07:02, HLA-B*42:01 and HLA-B*42:02. This
peptide and HLA-B*81:01 compared to the other HLAIs. (E) HLA-B*42:02
LA-B*42:01. This polymorphism reduces the interactions between residue
Table 3 HLA-RM9 contact table
B0702 B8101 B4201 B4202
TL9 VdW HB/SB VdW HB/SB VdW HB/SB VdW HB/SB
Arg1 37 5 35 4 30 4 30 4
Pro2 23 0 22 0 26 0 21 1
Gln3 27 1 23 2 24 2 26 2
Val4 2 0 2 0 2 0 2 0
Pro5 12 0 10 1 8 0 9 0
Leu6 17 0 6 0 4 0 10 0
Arg7 17 4 4 0 11 0 11 0
Pro8 9 1 9 0 15 1 14 1
Leu9 31 5 30 5 56 10 30 4
Total 175 16 141 12 176 17 153 12
BSA (Å) 1813.8 1843.4 1720.2 1796
SC (Å) 0.757 0.751 0.797 0.807
HB = hydrogen bond, SB = salt bridge, vdW = van der Waals interactions, BSA = buried surface area, SC = surface complementarity.
*A 3.4 Å cut-off was used for HBs and SBs, and a 4 Å cut-off was used for vdW.
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position within HLA-B*42:01 and HLA-B*42:02, but
moved by 3 Å in HLA-B*81:01 and 1.5 Å in HLA-B*07:02
(Figure 4B). These differences were mediated by polymor-
phisms at residues 156 and 152 within the α2 helix. The
larger side chains of Arg156 and Gln152 in HLA-B*07:02
pushed Leu6 up compared to the smaller side chains of
Leu156 and Val152 in HLA-B*81:01 (Figure 4C), changes
which may be linked to the L76V/T/I selection that is me-
diated only by HLA-B*81:01.
The other two major differences in RM9-Nef peptide
presentation were located at the junction between HLAI
residue 147 and peptide residue Pro8, and between
HLAI residue Tyr9 and peptide residue Pro2. The
smaller side chain of Leu147 in HLA-B*81:01 formed no
contacts with Pro8, whereas Trp147 in the 3 other
HLAIs made multiple interactions with Pro8 (Figure 4D).
Similarly, in all but HLA-B*42:02, in which the side
chain of His9 was too short, Tyr9 could contact Pro2
(Figure 4E). These differences could explain the slightly
reduced stability of RM9 bound to HLA-B*81:01 and
HLA-B*42:02 (Figure 2B,D).Discussion
Taken together, these data demonstrate that, from the
perspective of the TCR, TL9-p24 ‘looks’ completely dif-
ferent in the context of HLA-B*81:01 than it does in the
context of HLA-B*07:02 or HLA-B*42:01. This differ-
ence in potential TCR contact residues is consistent with
the differential viral escape patterns observed between
these closely related HLAI molecules. Indeed, 4 of these
differences are only selected by HLA-B*81:01, of which
two impact on viral replicative capacity [13].We were unable to generate enough soluble HLA-
B*42:02-TL9 protein to generate a crystal structure, con-
sistent with the low stability and lack of recognition of
this pHLAI [7]. HLA-B*42:02 has a unique polymorph-
ism within the B-pocket and contains His at residue 9 as
opposed to Tyr9 in HLA-B*07:02, HLA-B*42:01 and
HLA-B*81:01 molecules. Tyr9 in HLA-B*07:02, HLA-
B*42:01 made direct contacts with the primary N-terminal
anchor residue (Pro2) in the TL9-p24 peptide. Thus, His
at peptide position 9 could alter this interaction and desta-
bilise the HLA-B*42:02-TL9 complex. This notion is con-
sistent with the lack of detectable responses observed
to TL9-p24 in HLA-B*42:02 individuals [7], and is
most likely a result of the low HLA-B*42:02-TL9 sta-
bility demonstrated here by both peptide-HLAI off-
rates and by temperature dependent circular dichroism
experiments.
The four closely-related RM9-Nef peptide-HLAI struc-
tures show that similar conformations do not preclude
HLAI-specific selection pressures, such as for R71K, that
is only observed in the context of HLA-B*07:02. Our
structural analysis demonstrated that R71 (position 1 in
the peptide) pointed up, away from the HLAI groove
and could therefore act as a putative TCR contact. In-
deed, our previous work has shown that N-terminal pep-
tide residue 1 can serve as an important TCR contact
[20] in some systems. However, direct binding by a TCR
to this residue would depend on the overall orientation
of the TCR as most contacts are usually made with the
central bulge of the peptide (normally residues 4–6 in the
canonical 9-mer peptide). Thus, sensitivity to changes at
peptide N-terminal position 1 would likely be highly
dependent on the TCR sequence deployed by T-cells
recognising RM9-Nef in the context of divergent HLAIs.
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tion are likely different depending on the HLA type, we
speculate that HLA-B*07:02 expressing individuals may
select a TCR, sensitive to the R71K mutation, that is not
selected in HLA-B*42:01/42:02/81:01 positive individuals.
TCR structures obtained from HLA-B*07:02 restricted
RM9 specific T-cell clones sensitive to the R71K mutation
are needed to investigate this notion further. These find-
ings further highlight that HLA-allele specific HIV se-
quence changes at a population level are a highly sensitive
measure of HLA-allele specific selective immune pressure.
Finally, these data demonstrate that a substantial alter-
ation of the conformation of peptide residue P6 in the
HLA-B*81:01-RM9 complex is, as with the TL9-p24
Gag-HLA-B*81:01 structure, associated with the differ-
ential selection of escape mutations observed in vivo.
These observations in relation to both the TL9-p24 and
RM9-Nef epitopes support the notion that different re-
striction elements presenting the same viral epitope in a
structurally distinct conformation have an impact on the
patterns of viral escape and, thereby, potentially also on
immune control.
Conclusions
These data suggest that identical peptides presented
through subtly different HLAI alleles can be recognized as
distinct epitopes and provide a novel structural mechan-
ism for previously observed differential HLA allele specific
patterns of HIV-1 escape and disease progression.
Methods
Study subjects and HIV-1 sequence analysis
We studied 1,327 adults with chronic antiretroviral ther-
apy (ART)-naïve C-clade HIV-1 infection recruited from
Durban, South Africa [8,9] and from the Thames Valley
Cohort, United Kingdom [21]. Informed consent was
obtained from all participating individuals, and institu-
tional review boards at the University of KwaZulu-Natal,
Massachusetts General Hospital, and the University of
Oxford approved the study. HIV-1 sequences from Gag
and Nef proteins were generated [8] and analyzed [9] as
previously described.
IFNγ ELISPOT
The HIV-1 specific CD8+ T-cell responses were de-
termined in gamma interferon (IFNγ) enzyme-linked
immunospot (ELISPOT) assays. Frequencies of individ-
uals targeting TL9-p24 contained within overlapping
peptide (OLP)-25 (GATPQDLNTMLNTVGGH) and indi-
viduals targeting RM9-Nef contained within OLP-76
(EVGFPVRPQVPLRPMTFK) were determined by screen-
ing a total of 1,009 individuals as previously described
[8,14,22], of which n = 76 where HLA-B*07:02+, n = 154
where HLA-B*42:01+, n = 22 where HLA-B*42:02+ andn = 96 where HLA-B*81:01+. Individuals expressing HLA-
B*39:10 (n = 30) were excluded as they also target TL9-
p24 and RM9-Nef.
pHLAI stability assays
The measurement of pHLAI stability was determined with
a dissociation assay based on radiolabeled β2m and biotinyl-
ated HLAI, as recently described [23]. Briefly, biotinylated
HLAI heavy chain, 125I-labeled β2m, and peptide were
allowed to fold into pHLAI complexes in streptavidin-
coated scintillation microplates (Flashplate PLUS, Perkin
Elmer, Boston, MA) for 24 h at 18°C. Excess of unlabeled
β2m was added and dissociation was initiated by placing
the microplate in a scintillation reader (TopCount NXT,
Perkin Elmer, Boston, MA) operating at 37°C. The scintil-
lation signal was monitored by continuous reading of the
microplate for 24 h. Half-lives were calculated from dissoci-
ation curves using the exponential decay equation in Prism
v.5.0a (GraphPad, San Diego, CA). Assays were performed
in duplicate; the mean value of two experiments is reported.
Additionally, the thermal stability of HLA-B complexes
was assessed by circular dichroism (CD) spectroscopy
monitoring the change in ellipticities at 218 nm. Data were
collected on an Aviv Model 215 spectropolarimeter (Aviv
Biomedical Inc., Lakewood, NJ) using an 0.1-cm quartz
cell. Proteins were dissolved in PBS at concentrations of 3
μM. Melting curves were recorded in 0.5°C intervals from
4°C up to a maximum temperature when protein aggrega-
tion was observed. Melting curves were analyzed assum-
ing a two-state trimer-to-monomer transition from the
native (N) to unfolded (U) conformation N3 ↔ 3U with
an equilibrium constant K = [U]3/[N3] = F/[3c
2(1-F)3]
where F and c are the degree of folding and protein con-
centration, respectively. Data were fitted as described [24].
Fitted parameters were the melting temperature Tm, van’t
Hoff ’s enthalpy ΔHvH, and the slope and intercept of the
native baseline. As all protein complexes aggregated to
various degrees upon unfolding, the ellipticity of the un-
folded state was set as a constant of −1.36 M−1 cm−1 [25].
Construct design
The HLAI heavy chains and β2m chain were generated by
PCR mutagenesis (Stratagene) and PCR cloning. All se-
quences were confirmed by automated DNA sequencing
(Lark Technologies). The HLAI heavy chains (residues 1–
248) (α1, α2 and α3 domains), and β2m (residues 1 – 100)
were also cloned and used to make the pHLAI complexes.
The HLAI α chains and β2m sequences were inserted into
separate pGMT7 expression plasmids under the control of
the T7 promoter [2].
Protein expression, refolding and purification
Competent Rosetta DE3 E.coli cells were used to pro-
duce the HLAI heavy chains and β2m in the form of
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pression and proteins were chemically refolded as de-
scribed previously [26,27].Crystallization, diffraction data collection and model refinement
All protein crystals were grown at 18°C by vapour diffu-
sion via the sitting drop technique. 200 nL of each pHLAI
(10 mg/ml) in crystallization buffer (10 mM Tris pH 8.1
and 10 mM NaCl) was added to 200 nL of reservoir solu-
tion. HLA-B*07:02-TL9 crystals were grown in 22% PEG
4000 and 0.2 M ammonium sulphate, 0.1 M sodium acet-
ate [28]; HLA-B*81:01-TL9 crystals were grown in TOPS4
in 0.1 M HEPES pH 7.0, 20% PEG 4000 and 0.2 M am-
monium sulphate [28]; HLA-B*42:01-TL9 crystals were
grown in 10% PEG 6000, 10 mM magnesium chloride;
HLA-B*07:02-RM9 crystals were grown in TOPS in 0.1 M
sodium cacodylate pH 6, 15% PEG 8000 and 15% glycerol
[28]; HLA-B*81:01-RM9 crystals were grown in TOPS in
0.1 M Tris pH 8.0, 15% PEG 4000 and 15% glycerol [28];
HLA-B*42:01-RM9 crystals were grown in 10% PEG 6000,
10 mM magnesium chloride; HLA-B*42:02-RM9 crystals
were grown in 10% PEG 6000, 10 mM magnesium chlor-
ide [28]. All crystals were soaked in 30% ethylene glycol
before cryo-cooling. All crystallization screens and
optimization experiments were completed using an Art-
Robbins Phoenix dispensing robot (Alpha Biotech Ltd,
UK). Data were collected at 100 K at the Diamond Light
Source, Oxfordshire, UK. All datasets were collected at a
wavelength of 0.98 Å using an ADSC Q315 CCD detector.
Reflection intensities were estimated with the XIA2 pack-
age (Winter G.) and the data were scaled, reduced and an-
alyzed with SCALA and the CCP4 package (Collaborative
Computational Project 1994). Structures were solved with
molecular replacement using PHASER [29]. Sequences
were adjusted with COOT [30] and the models refined
with REFMAC5. Graphical representations were prepared
with PYMOL (DeLano, 2002). The reflection data and
final model coordinates were deposited with the PDB
database (HLA-B*07:02-TL9, PDB: 4U1H; HLA-B*81:01-
TL9, PDB: 4U1I; HLA-B*42:01-TL9, PDB: 4U1J; HLA-
B*07:02-RM9, PDB: 4U1K; HLA-B*81:01-RM9, PDB:
4U1L; HLA-B*42:01-RM9, PDB: 4U1M; HLA-B*42:02-
RM9, PDB: 4U1N).Additional file
Additional file 1: Tables S1 and S2. Supplementary information.Abbreviations
HLAI: Human leukocyte antigen class I; TCR: T cell receptor.
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